Abstract
Background: Coronavirus disease 2019 (COVID-19) is a respiratory disease associated with vascular inflammation and endothelial injury.
Objectives: To correlate circulating angiogenic markers vascular endothelial growth factor A (VEGF-A), placental growth factor (PlGF), and fibroblast growth factor 2 (FGF-2) to in-hospital mortality in COVID-19 adult patients.
Methods: Consecutive ambulatory and hospitalized patients with COVID-19 infection were enrolled. VEGF-A, PlGF, and FGF-2 were measured in each patient ≤48 h following admission.
Results: The study enrolled 237 patients with suspected COVID-19: 208 patients had a positive diagnostic for COVID-19, of whom 23 were mild outpatients and 185 patients hospitalized after admission. Levels of VEGF-A, PlGF, and FGF-2 significantly increase with the severity of the disease (P < .001). Using a logistic regression model, we found a significant association between the increase of FGF-2 or PlGF and mortality (odds ratio [OR] 1.11, 95% confidence interval [CI; 1.07-1.16], P < .001 for FGF-2 and OR 1.07 95% CI [1.04-1.10], P < .001 for PlGF) while no association were found for VEGF-A levels. Receiver operating characteristic curve analysis was performed and we identified PlGF above 30 pg/ml as the best predictor of in-hospital mortality in COVID-19 patients. Survival analysis for PlGF confirmed its interest for in-hospital mortality prediction, by using a Kaplan-Meier survival curve (P = .001) and a Cox proportional hazard model adjusted to age, body mass index, D-dimer, and C-reactive protein (3.23 95% CI [1.29-8.11], P = .001).
Conclusion: Angiogenic factor PlGF is a relevant predictive factor for in-hospital mortality in COVID-19 patients. More than a biomarker, we hypothesize that PlGF blocking strategies could be a new interesting therapeutic approach in COVID-19.
Keywords: COVID-19; FGF-2; PlGF; angiogenesis; mortality; placental growth factor.
【저자키워드】 COVID-19, Mortality, Angiogenesis, placental growth factor, FGF-2, PlGF, 【초록키워드】 coronavirus disease, Coronavirus disease 2019, Biomarker, severity, Infection, diagnostic, C-reactive protein, D-dimer, Angiogenesis, body mass index, COVID-19 infection, Respiratory disease, Patient, Mild, placental, age, endothelial injury, respiratory, Admission, in-hospital mortality, COVID-19 patients, association, marker, Outpatient, Therapeutic approach, Analysis, survival analysis, Odds ratio, best, Predictive, receiver operating characteristic, body mass, fibroblast growth factor, endothelial, Vascular, survival curve, 95% CI, 95% confidence interval, logistic regression model, VEGF, COVID-19 adult patients, circulating, growth factor, positive, vascular inflammation, fibroblast, Cox proportional hazard model, Kaplan-Meier survival curve, enrolled, significantly, the disease, was performed, adjusted, hospitalized patient, Level, were measured, Angiogenic, patients hospitalized, with COVID-19, 【제목키워드】 COVID-19 severity, plasma, predict, growth factor,